» Articles » PMID: 11920757

Tacrolimus is a Class II Low-solubility High-permeability Drug: the Effect of P-glycoprotein Efflux on Regional Permeability of Tacrolimus in Rats

Overview
Journal J Pharm Sci
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2002 Mar 29
PMID 11920757
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study is to investigate the role of P-glycoprotein (P-gp), a membrane efflux pump associated with multidrug resistance (MDR) and a known substrate for tacrolimus, in determining the regional intestinal permeability of tacrolimus in rats. Thus, isolated segments of rat jejunum, ileum, or colon were perfused with tacrolimus solutions containing polyethoxylated hydrogenated castor oil 60 surfactant, and with or without verapamil, a P-gp substrate used to reverse the MDR phenotype. The results indicated that the intrinsic permeability of tacrolimus in the jejunum, calculated on the basis of the concentration of non-micellized free tacrolimus, was quite high ( approximately 1.4 x 10(-4) cm/s). The apparent permeability (P(app)) in the jejunum was unaffected by the presence of verapamil; however, the P(app) in the ileum and the colon increased significantly in the presence of verapamil and were similar to the values observed in the jejunum. The results suggest that systemic absorption of tacrolimus from the gastrointestinal tract could be significantly affected by P-gp efflux mechanisms. It is also possible that differences in P-gp function at various intestinal sites in a subject or at a given intestinal site in various subjects could lead to large intra- and interindividual variability in bioavailability of tacrolimus following oral administration.

Citing Articles

Integrating In Vitro Dissolution and Physiologically Based Pharmacokinetic Modeling for Generic Drug Development: Evaluation of Amorphous Solid Dispersion Formulations for Tacrolimus.

Karakitsios E, Angelerou M, Kapralos I, Tsakiridou G, Kalantzi L, Dokoumetzidis A Pharmaceutics. 2025; 17(2).

PMID: 40006594 PMC: 11858865. DOI: 10.3390/pharmaceutics17020227.


Establishment of Biopredictive Dissolution and Bioequivalence Safe Space Using the Physiologically Based Biopharmaceutics Modeling for Tacrolimus Extended-Release Capsules.

Bi F, Yuan T, Zhang B, Li J, Lin Y, Yang J AAPS PharmSciTech. 2024; 26(1):13.

PMID: 39690309 DOI: 10.1208/s12249-024-03006-2.


Biphasic Calcium Phosphate and Activated Carbon Microparticles in a Plasma Clot for Bone Reconstruction and In Situ Drug Delivery: A Feasibility Study.

Rekima S, Gautier N, Bonnamy S, Rochet N, Olivier F Materials (Basel). 2024; 17(8).

PMID: 38673106 PMC: 11051311. DOI: 10.3390/ma17081749.


Investigating Tacrolimus Disposition in Paediatric Patients with a Physiologically Based Pharmacokinetic Model Incorporating CYP3A4 Ontogeny, Mechanistic Absorption and Red Blood Cell Binding.

Van der Veken M, Brouwers J, Ozbey A, Umehara K, Stillhart C, Knops N Pharmaceutics. 2023; 15(9).

PMID: 37765200 PMC: 10536648. DOI: 10.3390/pharmaceutics15092231.


Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: A comparison of Michaelis-Menten and theory-based pharmacokinetic models.

Cai X, Li R, Li J, Tao Y, Zhang Q, Shen C Front Pharmacol. 2022; 13:1031969.

PMID: 36438793 PMC: 9681907. DOI: 10.3389/fphar.2022.1031969.